Skip to main content

Table 1 Baseline demographic and disease characteristics

From: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

 Lanreotide autogel
(N = 64)
Lanreotide 40 mg PR (N = 64)All patients
(N = 128)
Age, years
 Mean (SD)37.9 (11.2)40.8 (12.6)39.4 (11.9)
Sex, n (%)
 Male26 (40.6)24 (37.5)50 (39.1)
 Female38 (59.4)40 (62.5)78 (60.9)
BMI, kg/m2
 Mean (SD)26.3 (3.6)26.1 (3.6)26.2 (3.6)
Time since acromegaly, years
 Mean (SD)3.70 (5.83)3.14 (4.09)3.42 (5.02)
Previous treatment, n (%)
 Pituitary surgery44 (68.8)44 (68.8)88 (68.8)
 Radiotherapy3 (4.7)3 (4.7)6 (4.7)
Any acromegaly medication ≤ 6 months prior to study entry, n (%)10 (15.6)12 (18.8)22 (17.2)
Tumor assessment at baseline by central evaluation, n (%)(n = 63)(n = 64)(n = 127)
 Microadenomaa15 (23.4)12 (18.8)27 (21.1)
 Macroadenomaa43 (67.2)47 (73.4)90 (70.3)
 No tumor5 (7.8)5 (7.8)10 (7.8)b
Solid component (μL)(n = 58)(n = 57)(n = 115)
 Mean (SD)4990.5 (8752.8)2589.1 (2666.5)3800.2 (6576.7)
  1. Data are presented from the intention-to-treat population. aTumor diameters: ≤10 mm were classified as microadenomas and > 10 mm as macroadenomas. bPatients who had no tumors at baseline had GH levels ranging from 3.3–24.3 μg/L in the lanreotide autogel group (n = 5), and 2.8–13.0 μg/L in the lanreotide 40 mg PR group (n = 5). BMI body mass index, GH growth hormone, PR prolonged release, SD standard deviation